XOMA
XOMA Royalty·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Three Black Crows
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XOMA
Xoma Royalty Corporation
A biotechnology royalty aggregator that develops antibodies and recombinant proteins to treat infectious and immunological diseases
2200 Powell Street, Suite 310, Emeryville, California 94608
--
XOMA Royalty Corporation, a Nevada company. The company is a biotechnology royalty aggregator that plays a unique role in helping biotech companies achieve their goals of improving human health. The company obtains potential future economics related to pre-commercialized and commercialized therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
Company Financials
EPS
XOMA has released its 2025 Q3 earnings. EPS was reported at 0.7, versus the expected -0.04, beating expectations. The chart below visualizes how XOMA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XOMA has released its 2025 Q3 earnings report, with revenue of 9.35M, reflecting a YoY change of 29.93%, and net profit of 14.05M, showing a YoY change of 181.49%. The Sankey diagram below clearly presents XOMA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
